USPTO serial 79342589
ASTARTZ
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Aug 22, 2023
- Examiner
- EISNACH, MICHAEL PATRICK
- Law office
- TMEG LAW OFFICE 104
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with ASTARTZ?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Tokyo 136-0075, JP
Tokyo 136-0075, JP
Tokyo 136-0075, JP
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Marina Dostal
Marina Dostal GE Precision Healthcare LLC3000 N Grandview BoulevardIP Department (Mail Code W-436)Waukesha, WI 53188Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Industrial chemicals; chemical preparations for scientific purposes; diagnostic reagents for scientific or research use; chemicals for use in the manufacture of pharmaceuticals; chemicals for use in the manufacture of radiopharmaceuticals; radioactive elements for scientific purposes; isotopes for industrial purposes; peptide substrates for scientific purposes; peptide for use in the manufacture of pharmaceuticals; chelating agents for use in the manufacture of pharmaceuticals; polypeptides for scientific purposes; antibodies for scientific purposes, other than for medical or veterinary use; chelate compound; organic chelating agents; metal chelating agents | ACTIVE | — |
| 005 | Pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the diagnosis of cancer; chemical reagents for medical purposes; medical diagnostic reagents; radioactive substances for medical purposes; isotopes for medical purposes; radioisotope markers for therapeutic or diagnostic use; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; synthetic peptides for pharmaceutical purposes for the treatment of cancer; synthetic peptides for pharmaceutical purposes for the diagnosis of cancer; pharmaceuticals consisting of antibodies for the treatment of cancer; pharmaceuticals consisting of antibodies for the diagnosis of cancer; pharmaceuticals consisting of antibody fragments for the treatment of cancer; pharmaceuticals consisting of antibody fragments for the diagnosis of cancer; pharmaceuticals consisting of antibody derivatives for the treatment of cancer; pharmaceuticals consisting of antibody derivatives for the diagnosis of cancer; antibodies for medical purposes | ACTIVE | — |
| 040 | Custom manufacture of pharmaceuticals; custom manufacture of investigational new drug; custom manufacture of radiopharmaceuticals; custom synthesis of labeled compound; custom manufacture of peptides; custom manufacture of antibodies; custom manufacture of proteins; custom protein modification; custom antibody modification; custom extraction of pharmaceuticals and veterinary preparations; custom synthesis and refining of pharmaceuticals and veterinary preparations; custom peptide synthesis services; custom synthesis and refining of pharmaceuticals consisting of antibodies; custom manufacture of pharmaceuticals consisting of antibodies; custom synthesis and refining of pharmaceuticals consisting of antibody fragments; custom manufacture of pharmaceuticals consisting of antibody fragments; custom synthesis and refining of pharmaceuticals consisting of antibody derivatives; custom manufacture of pharmaceuticals consisting of antibody derivatives; custom radioactive labeling of antibodies; custom radioactive labeling of antibody fragments; custom radioactive labeling of antibody derivatives; custom radioactive labeling of peptides | ACTIVE | — |
| 042 | Research and development of medicines; testing, inspection or research services in the fields of pharmaceuticals; advisory, consultancy and providing information relating to testing, inspection or research services in the fields of pharmaceuticals; development of pharmaceuticals; advisory, consultancy and providing information relating to development of pharmaceuticals; conducting clinical trials for pharmaceuticals for others; advisory, consultancy and providing information relating to clinical trials for pharmaceuticals; research and development of radiopharmaceuticals; development of radiopharmaceuticals; advisory, consultancy and providing information relating to development of radiopharmaceuticals; research and development services relating to peptides; research and development services in the field of antibodies; research and development services relating to peptide labeling by radioactive substances; research and development services relating to antibody labeling by radioactive substances | ACTIVE | — |
| 045 | Granting of licenses to others for the use of intellectual property; legal services, namely, exploitation of industrial property rights | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by NIHON MEDI-PHYSICS CO., LTD.
- Other trademarks owned by NIHON MEDI-PHYSICS CO., LTD.
- Other trademarks owned by NIHON MEDI-PHYSICS CO., LTD.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named ASTARTZ
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 17, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 17, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 17, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Oct 17, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Oct 17, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 18, 2024 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| May 10, 2024 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| May 9, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Dec 19, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 27, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Nov 27, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Nov 22, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 28, 2023 | ES7R | TEAS SECTION 7 REQUEST RECEIVED | — |
| Aug 22, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Aug 22, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 6, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jun 6, 2023 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jun 6, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 6, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| May 17, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| May 17, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| May 17, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| May 15, 2023 | APET | ASSIGNED TO PETITION STAFF | — |
| May 1, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 1, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| May 1, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| May 1, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 26, 2023 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Apr 25, 2023 | PBMR | WITHDRAWN FROM PUB - MANAGING ATTORNEY REQUEST | — |
| Apr 22, 2023 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Apr 19, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Apr 18, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 17, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 17, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 6, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 15, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 15, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Dec 20, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Dec 19, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 9, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 30, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Jun 28, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 23, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 22, 2022 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jun 16, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |